following an abbreviated submission:
bimekizumab (Bimzelx®) is accepted for use within NHSScotland.
Indication under review: axial spondyloarthritis
- For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).
- For the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
Bimekizumab offers an additional treatment choice in the therapeutic class of immunosuppressants for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice251KB (PDF)
Medicine details
- Medicine name:
- bimekizumab (Bimzelx)
- SMC ID:
- SMC2616
- Indication:
For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs)
and
adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 December 2023